PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för auranofin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

12 hits

Bibliografisk träff 2012-06-01

A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target.

Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, Chen S, García-Rivera G, Orozco E, Martínez MB, Gunatilleke SS, Barrios AM, Arkin MR, Poole LB, McKerrow JH, Reed SL.

Nat Med · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/nm.2758

Bibliografisk träff 2010-02-01

Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drug.

Kast RE.

Cent Eur Neurosurg · review; journal article · DOI 10.1055/s-0029-1242756

Bibliografisk träff 2008-08-26

The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation.

Cox AG, Brown KK, Arner ES, Hampton MB.

Biochem Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2008.08.021

Bibliografisk träff 2008-03-01

Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells.

Han S, Kim K, Song Y, Kim H, Kwon J, Lee YH, Lee CK, Lee SJ, Ha N, Kim K.

Arch Pharm Res · research support, non-u.s. gov't; journal article · DOI 10.1007/s12272-001-1166-9

Bibliografisk träff 2007-07-20

Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.

Kim NH, Lee MY, Park SJ, Choi JS, Oh MK, Kim IS.

Immunology · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1365-2567.2007.02679.x

Bibliografisk träff 2005-07-01

Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase.

Rigobello MP, Folda A, Baldoin MC, Scutari G, Bindoli A.

Free Radic Res · research support, non-u.s. gov't; journal article · DOI 10.1080/10715760500135391

Bibliografisk träff 2000-09-01

Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis.

Liu J, Akahoshi T, Namai R, Matsui T, Kondo H.

Inflamm Res · research support, non-u.s. gov't; journal article · DOI 10.1007/s000110050615

Bibliografisk träff 2000-01-01

Auranofin versus placebo in rheumatoid arthritis.

Suarez-Almazor ME, Spooner CH, Belseck E, Shea B.

Cochrane Database Syst Rev · systematic review; systematic-review; journal article · DOI 10.1002/14651858.cd002048

Bibliografisk träff 1997-05-01

Auranofin.

Kean WF, Hart L, Buchanan WW.

Br J Rheumatol · review; journal article · DOI 10.1093/rheumatology/36.5.560

Bibliografisk träff 1989-05-01

Oral chrysotherapy with auranofin in dogs.

Serra DA, White SD.

J Am Vet Med Assoc · review; journal article · DOI 10.2460/javma.1989.194.09.1327

Bibliografisk träff 1984-05-01

Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Chaffman M, Brogden RN, Heel RC, Speight TM, Avery GS.

Drugs · comparative study; clinical trial; review; journal article · DOI 10.2165/00003495-198427050-00002

Bibliografisk träff 1984-03-01

Review of auranofin, an oral chrysotherapeutic agent.

Delafuente JC, Osborn TG.

Clin Pharm · review; journal article